Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $18.00 by Analysts at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price lowered by investment analysts at HC Wainwright from $27.00 to $18.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 195.08% from the company’s current price. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ FY2029 earnings at ($6.62) EPS.

Several other analysts have also recently weighed in on ENTA. JMP Securities restated a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird cut their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Trading Down 4.2 %

Shares of Enanta Pharmaceuticals stock opened at $6.10 on Tuesday. The firm’s 50 day moving average is $9.52 and its 200 day moving average is $11.61. The firm has a market capitalization of $129.28 million, a PE ratio of -1.11 and a beta of 0.49. Enanta Pharmaceuticals has a 1 year low of $5.70 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter last year, the company posted ($1.33) earnings per share. The firm’s quarterly revenue was down 22.8% on a year-over-year basis. As a group, research analysts anticipate that Enanta Pharmaceuticals will post -4.73 earnings per share for the current year.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.64% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Krensavage Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after purchasing an additional 246,736 shares in the last quarter. Geode Capital Management LLC lifted its stake in Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after buying an additional 14,575 shares during the period. State Street Corp boosted its holdings in shares of Enanta Pharmaceuticals by 6.4% during the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after buying an additional 27,147 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $1,243,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at $903,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.